Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS
Neurology2005Vol. 65(11), pp. 1834–1836
Citations Over TimeTop 10% of 2005 papers
Kimberly L. Ferrante, Jeremy M. Shefner, H. Zhang, Rebecca A. Betensky, Mike O’Brien, Hailing Yu, Martha A. Fantasia, J Taft, M. Flint Beal, Bryan Traynor, Kristyn Newhall, P. D. Donofrio, James B. Caress, C. Ashburn, Barbara Loggan Freiberg, Christine J. O’Neill, Connie Paladenech, Tracey Walker, Alan Pestronk, Berenice Abrams, J. Florence, Renee Renna, Jeanine Schierbecker, Betsy Malkus, Merit Cudkowicz
Abstract
An open-label dose-escalation trial was performed to assess the safety and tolerability of high doses of coenzyme Q10 (CoQ10) in ALS. CoQ10, a cofactor in mitochondrial electron transfer, may improve the mitochondrial dysfunction in ALS. In this study, CoQ10 was safe and well tolerated in 31 subjects treated with doses as high as 3,000 mg/day for 8 months.
Related Papers
- → Coenzyme Q–dependent mitochondrial respiratory chain activity in granulosa cells is reduced with aging(2015)55 cited
- → Treatment of Kearns‐Sayre syndrome with coenzyme Q 10(1986)158 cited
- → Effect and structure-activity relationship of the coenzymes Q on the phagocytic rate of rats(1972)22 cited
- → [57] Coenzyme Q and analogs for coenzymic activity(1978)24 cited
- → Trends in coenzyme Q10 research.(1985)2 cited